Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Choline fenofibrate - AbbVie

X
Search
Drug Profile

Choline fenofibrate - AbbVie

Alternative Names: ABT-335; Fenofibric acid choline salt; HEXA/ABT335; SLV 348; SLV348/ABT335; TriLipix

Latest Information Update: 07 Sep 2021

Price : ¥7190 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Solvay
  • Developer AbbVie
  • Class Antihyperlipidaemics; Chlorobenzenes; Ethanolamines; Fibric acid derivatives; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipidaemia
  • Discontinued Diabetic macular oedema

Most Recent Events

  • 07 Sep 2021 Discontinued - Phase-II for Diabetic macular oedema in European Union (PO)
  • 07 Sep 2021 Discontinued - Phase-III for Hyperlipidaemia (Combination therapy) in Puerto Rico (PO)
  • 12 Oct 2015 No recent reports on development identified - Phase-III for Hyperlipidaemia (Combination therapy) in Puerto Rico (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days